KLOW – TB-500 10mg / BPC-157 10mg / KPV 10mg / GHK-Cu 50mg

For research use only — not for human or veterinary use.

Analytical Verification (COA)

Each batch of KLOW supplied by Grail Formula undergoes independent third-party laboratory verification to confirm compound identity, assay composition, purity and microbiological safety.

Analytical testing for this batch was performed by Liquilabs s.r.o. (Czechia) using validated chromatographic and spectrometric techniques.

Batch: GF-KLOW-B241

Key analytical results include:

• GHK-Cu: 65.5 mg
• BPC-157: 12.09 mg
• KPV: 10.47 mg
• Thymosin Beta 4 (TB-500): 13.17 mg
• Identification (RT): all components verified within validated ranges
• Bacterial Endotoxins: below 0.001 EU per mg
• Total Aerobic Microbial Count: not detected
• Total Yeast and Mold Count: not detected

Independent heavy metal screening confirmed no detectable levels of arsenic, cadmium, cobalt, lead, nickel, mercury or vanadium.

These analytical procedures ensure traceability, composition accuracy and laboratory-grade consistency across all peptide components.

Product Overview

KLOW is a multi-peptide research formulation studied in controlled laboratory environments focused on peptide signalling pathways and molecular regulatory systems.

The formulation combines several synthetic peptides, each investigated in biochemical research for their interaction with signalling pathways and regulatory processes.

This preparation contains a total of 80 mg of high purity lyophilized peptide blend supplied in a sealed research vial. The lyophilization process preserves compound stability and allows researchers to reconstitute the formulation for controlled in vitro experimentation.

Due to its defined multi-compound structure and stable analytical profile, KLOW is frequently used in experimental peptide research models involving combination formulations.

Compound Overview

KLOW consists of a combination of synthetic peptides studied for their interaction with signalling pathways and regulatory systems.

Within experimental models, the formulation is commonly investigated for multi-pathway interactions and peptide synergy in controlled laboratory conditions.

The combination approach allows researchers to explore complex signalling interactions across multiple peptide systems.

Historical Background and Scientific Context

Scientific interest in multi-peptide formulations has increased as researchers explore the combined effects of peptide compounds within signalling networks.

Combination peptide research enables investigation into synergistic interactions and multi-target pathway modulation.

This has contributed to broader research into peptide-based regulatory systems and signalling complexity.

Mechanistic Focus in Research

Within experimental laboratory settings, KLOW is commonly studied in relation to multi-pathway peptide signalling.

Research investigations commonly explore the formulation in experimental models examining:

• Multi-peptide signalling pathways
• Regulatory network interactions
• Peptide synergy and interaction dynamics
• Intracellular signalling mechanisms
• Comparative peptide combination studies
• Molecular pathway integration
• Complex signalling modelling

These experimental models allow scientists to investigate interactions between multiple peptide systems and regulatory mechanisms.

Research Applications

In controlled research environments, KLOW may be utilised in experimental models designed to explore multi-peptide signalling systems and regulatory interactions.

Examples of research applications include:

• Peptide combination research
• Multi-pathway signalling studies
• Intracellular network modelling
• Comparative formulation studies
• Molecular interaction analysis
• Regulatory pathway research
• Controlled in vitro studies

Grail Formula Quality

Every Grail Formula research compound is produced under strict quality control procedures designed to support reliable laboratory experimentation.

Each batch undergoes independent analytical testing to verify:

• Compound identity
• Assay composition accuracy
• Purity confirmation
• Microbial safety
• Endotoxin levels
• Heavy metal screening
• Full batch traceability

All testing is performed by independent laboratories to ensure transparent verification and reproducible research material.

Research Use Limitation

• Used solely for in vitro experiments
• Not permitted for clinical trials involving humans
• Not permitted for human or veterinary administration
• Not permitted for investigational human use

• Independently analysed by Liquilabs s.r.o. Czechia
• Multi-peptide blend with verified assay composition
• GHK-Cu – 65.5 mg
• BPC-157 – 12.09 mg
• KPV – 10.47 mg
• Thymosin Beta 4 (TB-500) – 13.17 mg
• Endotoxin level below 0.001 EU/mg
• No detectable heavy metals or microbial contamination
• For research use only – not for human or veterinary use

For laboratory research only. Not intended for human consumption, injection, or cosmetic use.

This product is for research purposes only. Not for human use or diagnostic/therapeutic applications. Keep out of reach of children.